CStone Pharmaceuticals’ Sugemalimab Shows Promising Long-Term Survival Data at ESMO 202
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has presented long-term treatment and...
Company
Ascletis Pharma Initiates Phase I Trials for Monthly Subcutaneous and Daily Oral Obesity Treatment ASC30 in the US
Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced the dosing...
Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Dizal Pharmaceutical’s Sunvozertinib Shows Promising Results in WU-KONG Series Study at ESMO 2024
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has presented updates...
MicroPort Scientific’s Firesorb Bioabsorbable Stent Begins Clinical Use in China
MicroPort Scientific Corp., a leading medical device company based in Shanghai (HKG: 0853), has announced...
Merck’s Keytruda Gains Expanded Approval for First-Line Melanoma Treatment in China
Merck & Co., Inc. (NYSE: MRK), a leading US pharmaceutical company, has announced that its...
iTeos Therapeutics and GSK’s Belrestotug/Dostarlimab Combo Shows Promising Results in NSCLC
iTeos Therapeutics has announced the latest data from the Phase 2 platform study GALAXIES Lung-201,...
Merck and Daiichi Sankyo’s HER3-DXd ADC Patritumab Deruxtecan Passes Phase 3 Trial After FDA Rejection
Merck (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) announced that their antibody-drug conjugate (ADC) patritumab...
Kangfang Biotech Presents Groundbreaking mCRC Treatment Data at ESMO Congress
At the 2024 European Society for Medical Oncology (ESMO) Congress, Kangfang Biotech (HKG: 9926) debuted...
Kangfang Biotech’s Yivoxi Shows Promising Results in First-Line TNBC Treatment at ESMO Congress
At the 2024 European Society for Medical Oncology (ESMO) Congress, Kangfang Biotech (HKG: 9926) unveiled...
Kangfang Biotech’s Yivoxi Shows Promising Results in Treating R/M HNSCC at ESMO Congress
At the 2024 European Society for Medical Oncology (ESMO) Congress, Kangfang Biotech (HKG: 9926) unveiled...
Shanghai Pharmaceuticals’ Dual-Targeting CAR-T Therapy Advances with IND Re-Acceptance
Shanghai Pharmaceuticals Group Co., Ltd. (SHA: 601607)’s biotech subsidiary has announced that its investigational ‘CD19...
Walsun Biotech Achieves Top ESG Rating, Underscores Commitment to Sustainability
Yunnan Walsun Biotech Co., Ltd. has seen its ESG rating upgraded to BBB by MSCI,...
Novartis’ Cemiplimab Approved in China for Moderate-to-Severe Atopic Dermatitis
Novartis (SWX: NOVN, NYSE: NVS)’s Chinese arm has announced that it has received approval from...
Innovent Biologics Launches Phase I Clinical Trial for IBR822 Cell Injection Solution in Solid Tumors
Innovent Biologics (Hangzhou) Co., Ltd (HKG: 1801, OTCMKTS: IVBXF), a biopharmaceutical company based in China,...
Johnson & Johnson’s Tremfya Gains FDA Approval for Ulcerative Colitis Treatment
Johnson & Johnson (NYSE: JNJ) announced today that the US Food and Drug Administration (FDA)...
Sanofi Secures Global Rights to Radioligand Therapy AlphaMexi in Deal with RadioMedix and Orano Med
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has entered into a significant...
Roche’s Tecentriq Hybreza Becomes First Subcutaneous Anti-PD-(L)1 Immunotherapy in the US
Roche (SWX: ROG; OTCMKTS: RHHBY) , a leading Swiss pharmaceutical company, has secured US Food...
Lilly’s Once-Monthly Atopic Dermatitis Treatment Ebglyss Gets Green Light from FDA
Eli Lilly & Co. (NYSE: LLY) has announced that it has received market approval from...
Roche’s Ocrevus Zunovo Receives FDA Nod as First Twice-Yearly MS Treatment
Roche Group (SWX: ROG; OTCMKTS: RHHBY) , a Swiss pharmaceutical giant, has announced that the...